Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 3, 2005, Pages 301-306

  Fletcher, Courtney V ^a   Testa, Marcia A ^b   Brundage, Richard C ^c   Chesney, Margaret A ^d   Haubrich, Richard ^e   Acosta, Edward P ^f   Martinez, Ana ^d   Jiang, Hongyu ^b   Gulick, Roy M ^g  

^a UNIVERSITY OF COLORADO   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adherence; Antiretroviral therapy; Pill counts; Self reported adherence; Virologic response

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIRETROVIRUS AGENT; DELAVIRDINE; NELFINAVIR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG MONITORING; EVALUATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; ADULT; ANTI-RETROVIRAL AGENTS; CAPSULES; DOUBLE-BLIND METHOD; FEMALE; HIV; HUMANS; MALE; PATIENT COMPLIANCE; RNA, VIRAL; SAQUINAVIR; SELF CARE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 27444433808     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000180078.53321.6a     Document Type: Article

References (21)

1. McNabb JJ, Ross JW, Abriola K, et al. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33:700-705.
2. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
3. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitor, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366.
4. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
5. Sethi AK, Celentano DD, Gange SJ, et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37:1112-1118.
6. Walsh JC, Pozniak AL, Nelson MR, et al. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr. 2002;30:278-287.
7. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance. AIDS. 2003;17:1925-1932.
8. Samet JH, Sullivan LM, Traphagen E, et al. Measuring adherence among HIV infected persons: is MEMS consummate technology? AIDS Behav. 2001;5:21-29.
9. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968-977.
10. Gulick RM, Hu J, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000;182:1375-1384.
11. Gulick RM, Hu XJ, Fiscus SA, et al. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. J Infect Dis. 2002;186:626-633.
12. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instrument. AIDS Care. 2000;12:255-266.
13. Remmel RP, Kawle SP, Weller D, et al. A simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma. Clin Chem. 2000;46:73-81.
14. Beal SL, Sheiner LB. NONMEM Users Guides. San Francisco: NONMEM Project Group, University of California, San Francisco; 1992.
15. Fletcher CV, Acosta EP, Cheng H, et al. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS. 2000;14:2495-2501.
16. Fletcher CV, Jiang H, Brundage RC, et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group (ACTG) Study 359. J Infect Dis. 2004;189:1176-1184.
17. Yasuda J, Miller C, Little S, et al. Correlation between repeated measures of plasma concentrations of protease inhibitors, medication adherence, and virologic outcome in HIV-infected patients. Paper presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002; San Diego, CA.
18. Straka RJ, Fish JT, Benson SR, et al. Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy. 1997;17:126-132.
19. Brundage RC, Yong FH, Fenton T, et al. Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother. 2004;48:979-984.
20. McNabb JJ, Nicolau DP, Stoner JA, et al. Patterns of adherence to antiretroviral medications: the value of electronic monitoring. AIDS. 2003;17:1763-1767.
21. Mathews WC, Mar-Tang M, Ballard C, et al. Prevalence, predictors, and outcomes of early adherence after starting or changing antiretroviral therapy. AIDS Patient Care STDS. 2002;16:157-172.